aim of the review to systematically analyze the efficacy and safety of liraglutide for the treatment of diabetes mellitus in comparison to other mono and combination therapiesmethod pubmed any date and embase all years search was conducted with liraglutide as a search termphase iii clinical trials retrieved by the two databases and resources posted in drugfda website were evaluated with regard to outcomes of efficacy and safetyresults eight phase iii clinical studies compared the efficacy and safety of liraglutide to other monotherapies or combinationsliraglutide as monotherapy in doses of 09 mg or above showed a significantly superior reduction in hba1c compared to monotherapies with glimepiride or glyburidewhen liraglutide was used as addon therapy to glimepiride in doses of 12 mg or above the reduction of hba1c was greater than that in the combination therapy of glimepiride and rosiglitazonehowever liraglutide as addon therapy to metformin failed to show benefit over combination of metformin and glimepiridetriple therapy of using liraglutide in addition to metformin plus either glimepiride or rosiglitazone resulted in additional benefit in hba1c reductionmost common adverse events were gastrointestinal disturbance such as nausea vomit diarrhea and constipationduring the eight clinical studies six cases of pancreatitis and five cases of cancer were reported in liraglutide arm whereas there was one case of each of pancreatitis in exenatide and glimepiride arms respectively and one case of cancer in metformin plus sitagliptin armconclusion liraglutide is a new therapeutic option to improve glycemic control in patients with type 2 diabeteshowever the present lack of evidence of durability of efficacy and longterm safety appear to limit its utility in the general treatment of type 2 diabetes at this time